Nav: Home

Countdown economist and parasitologist call for efficient and equitable control of NTDs

June 10, 2016

The continuing permanence of major neglected tropical diseases (NTDs) is leading to a revision of the related research agenda towards current and future control interventions and associated targets. In the journal Lancet Infectious Diseases, published 7 June 2016, LSTM's Professors Louis Niessen and Russell Stothard argue for a broad research and implementation approach in an efficient and equitable upscaling of the control of schistosomiasis and soil-transmitted helminthiasis in Sub-Saharan Africa.

Set within a global strategy of preventive chemotherapy as endorsed by WHO, routine co-administration of the anthelminthics praziquantel (PZQ) and albendazole (ALB), by mass drug administration, is the frontline public health tool against schistosomiasis and soil-transmitted helminthiasis (STH), respectively. In 2012 several significant pledges and commitments made at the London Declaration on NTDs with an additional World Health Assembly (WHA) resolution 65.21 that called for intensification of efforts to better rally resources and to ensure an adequate provision of medications.

In their Comments Professors Niessen and Stothard give thoughtful support to a Stanford-based economics study on the situation in Sub-Saharan Africa by Nathan Lo and colleagues, published in the same journal, that demonstrates most strikingly that, if 20% of the entire population would shift to integrated treatment, fully dovetailing PZQ and ALB treatments, programme synergies would lead to a 40% reduction in implementation costs. Also, the study shows that annual preventive chemotherapy against schistosomiasis to be very likely cost-effective in treatment of school-aged children already at a prevalence of 5% (current guidelines state 50%) and of entire communities at 15% prevalence. Annual mass drug administration against STH is very likely cost-effective in treatment of school-aged children at a prevalence of 20% and for the entire community only as high as 60% prevalence, given uncertainties (95% UI: 35·3-85·1%). The authors estimate that treatment needs for Africa are six-fold higher than current guidelines for PZQ and two- fold higher for ALB.

Nathan Lo, the leading scientist, from Stanford University School of Medicine, said: "This editorial provides a clear vision on how our study findings can be translated into the next stage of helminthiasis control and elimination. Their words are optimistic for what we can accomplish to address the disease burden of helminths, but also realistic with many suggestions on how to address the host of challenges in revision of treatment guidelines and scaling up of treatment programmes."

Niessen and Stothard argue that the consequences for country programming are immense. The involved total budgets and other investments needed will be substantial, a major undertaking, given the limited resources in other priority areas within the NTD programmes and other health issues. In all scenarios, increased drug subsidies, and donations from pharmaceutical companies, strong political will, increased logistical support and improved epidemiological surveillance to monitor for drug resistance are needed. Although treatment expansion is now shown both financially and geographically appealing, Professor Niessen and colleague point out that extension of coverage is also justified ethically. At lower prevalence levels the at-risk vulnerable populations may be living in poverty and be harder to reach and lower compliance will lead to less returns. Extra effort and resources needed in the national process to improve the quality of the existing expanded MDA programmes in all places. Professor Stothard emphasizes that strategies need to be in place to ensure that treatment fatigue within the community does not dampen the recipients' compliance and that their demand for treatment continues to complement the donor landscape and health system.

Professor Niessen said: "In revising preventive chemotherapy guidelines based on these new estimates, broader quantitative and qualitative evidence should also be collected and incorporated and collected - such as through the LSTM-coordinated COUNTDOWN programme -- to optimise the implementation of control campaigns, which may suffer low uptake. At least, these developments are new and essential steps in the promotion of universal access in prevention and treatment of neglected tropical diseases as also envisaged in the sustainable development goals."

You can read the article here.
-end-


Liverpool School of Tropical Medicine

Related Schistosomiasis Articles:

Parasite paralysis: A new way to fight schistosomiasis?
Scientists have isolated a natural chemical that acts as a potent kryptonite against parasitic worms that burrow through human skin and cause devastating health problems.
Study shows interactions between bacteria and parasites
A team at the Technical University of Munich (TUM) has completed the first study of the effects of a simultaneous infection with blood flukes (schistosomes) and the bacterium Helicobacter pylori -- a fairly common occurrence in some parts of the world.
Super shrimp designed at Ben-Gurion University could increase yield and prevent disease
''We were able to achieve the monosex population without the use of hormones or genetic modifications and thus address two major agricultural considerations: monosex populations and ecological concerns,'' says Levy.
Poverty as disease trap
The realities of subsistence living in a region of Senegal hard hit by schistosomiasis make reinfection likely, despite mass drug administration.
How fat prawns can save lives
New research led by University of California, Berkeley, scientists provides a roadmap for how entrepreneurs can harness freshwater prawns' voracious appetite for snails to reduce the transmission of schistosomiasis-causing parasites while still making a profit selling the tasty animals as food.
Detection of unusual hybrid schistosomes in Malawi
LSTM's Professor Russell Stothard is senior author on a new paper in which researchers from the UK and Malawi have described the unusual occurrence of novel schistosome hybrids infecting children along the Shire River Valley.
Gene-editing tool CRISPR/Cas9 shown to limit impact of certain parasitic diseases
For the first time, researchers at the George Washington University have successfully used the gene-editing tool CRISPR/Cas9 to limit the impact of parasitic worms responsible for schistosomiasis and for liver fluke infection, which can cause a diverse spectrum of human disease including bile duct cancer. 
GW researchers publish review article on developing vaccines for human parasites
Researchers from the George Washington University published an article in Trends in Parasitology outlining their lessons learned while creating vaccine candidates for hookworm and schistosomiasis.
Finding a weak link in the frightful parasite Schistosoma
Researchers at the Morgridge Institute for Research shed light on the complex life cycle of Schistosoma, a parasite responsible for sickening hundreds of millions of people in the developing world.
Potential new drug for two life-threatening diseases
Derived from nature, a potential new drug to treat two life-threatening tropical diseases has been discovered as a result of collaboration between two Welsh universities.
More Schistosomiasis News and Schistosomiasis Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.